Data / Research funding / Tuberculosis
Tuberculosis: 1,132 NIH awards ($3.1B) to 245 organizations
1,132 NIH awards ($3.1B) in the NIH spending category Tuberculosis, to 245 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,132 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $84,840,845 | June 29, 2006 | November 30, 2027 | HUGHES, MICHAEL DAVID | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| SDMC - IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $59,233,299 | June 29, 2006 | November 30, 2027 | SHAPIRO, DAVID ERIC | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $20,605,531 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| UCSD Collaborative Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,116,542 | December 1, 2024 | November 30, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,134,028 | June 1, 2025 | June 30, 2026 | WOOLS-KALOUSTIAN, KARA KAY | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Central Africa International Epidemiology databases to Evaluate AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,957,495 | May 1, 2025 | April 30, 2027 | YOTEBIENG, MARCEL | reporter.nih.gov |
| Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,828,159 | May 13, 2021 | April 30, 2027 | RHEE, KYU Y | reporter.nih.gov |
| C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $15,575,398 | July 1, 2024 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,404,946 | May 1, 2025 | June 30, 2026 | CASTILHO, JESSICA L | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $14,399,999 | March 26, 2024 | February 28, 2029 | SAVIC, RADOJKA | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Metabolic determinants of Mtb virulence, vulnerability and variation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,485,680 | May 1, 2025 | April 30, 2027 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| TB-RICC 3.0 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,818,694 | April 1, 2023 | March 31, 2028 | ELLNER, JERROLD J. | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,202,199 | March 15, 2007 | September 21, 2025 | SANNE, IAN MATTHIAS | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,947,708 | February 5, 2007 | November 30, 2027 | GUPTA, AMITA | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Administrative Supplement Request for 2025 Systems Biology for Infectious Diseases Annual Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,511,156 | August 17, 2018 | May 31, 2028 | KROGAN, NEVAN J | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,824,534 | February 1, 2007 | June 30, 2025 | LOCKMAN, SHAHIN | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| FEND for TB supplement to accelerate BLINK X development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $8,340,332 | June 4, 2020 | May 31, 2025 | ELLNER, JERROLD J. | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,511,308 | September 10, 2021 | August 31, 2027 | SAMET, JEFFREY H. | reporter.nih.gov |
| Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,298,694 | May 25, 2016 | April 30, 2027 | DUDA, STEPHANY NORAH | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,434,161 | September 11, 2025 | August 31, 2029 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,559,114 | June 17, 2020 | January 31, 2027 | WALZL, GERHARD | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| Supplement to G20AI67347 to complete critical upgrades to the Rutgers RBL | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,241,770 | August 22, 2022 | February 29, 2024 | ALLAND, DAVID | reporter.nih.gov |
| Deep spatial immune profiling of granulomas and M. tuberculosis adaptation to disease and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,831,256 | December 1, 2021 | November 30, 2026 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $4,760,584 | September 23, 2025 | August 31, 2030 | NAHID, PAYAM | reporter.nih.gov |
| PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,716,636 | May 1, 2025 | April 30, 2027 | KOENIG, SERENA PATRICIA | reporter.nih.gov |
| Clinical Trial Site Monitoring for PHOENIx MDR-TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,653,435 | April 15, 2025 | December 14, 2025 | SMITH, KIMBERLY | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,608,548 | January 1, 2023 | December 31, 2023 | COFFIN, JEANETTE | reporter.nih.gov |
| T cell recognition of the MR1 presented microbial metabolome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,523,152 | July 10, 2019 | June 30, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Impact of tuberculosis on the development and function of the immune system in SIV-infected infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $4,476,086 | April 1, 2019 | March 31, 2025 | WANG, XIAOLEI | reporter.nih.gov |
| A systems analysis of drug tolerance in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,414,678 | December 1, 2016 | June 30, 2027 | BALIGA, NITIN S | reporter.nih.gov |
| Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,248,593 | July 1, 2025 | June 30, 2027 | AULD, SARA | reporter.nih.gov |
| Preventing TB with intravenous BCG in SIV-infected macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,442 | May 5, 2021 | April 30, 2026 | SCANGA, CHARLES A. | reporter.nih.gov |
| The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,208,331 | June 1, 2020 | July 31, 2030 | SESHADRI, CHETAN | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Capturing spatial patterns of new M. tuberculosis infection in Kampala, Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,188,624 | August 9, 2019 | July 31, 2026 | BARK, CHARLES MARTYN | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,152,012 | February 1, 2023 | January 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Mechanisms of Helicases, Translocases and SSB Proteins involved in Genome Maintenance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,120,970 | May 1, 2020 | July 31, 2030 | LOHMAN, TIMOTHY M | reporter.nih.gov |
| A STINGing vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,090,805 | June 1, 2020 | May 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Childhood Omics and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $4,076,080 | April 22, 2020 | August 31, 2025 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,042,959 | January 25, 2023 | December 31, 2027 | LOUIE, ARNOLD | reporter.nih.gov |
| Structure/Function of Transcription Complex Regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,041,062 | July 1, 1987 | August 31, 2027 | LANDICK, ROBERT | reporter.nih.gov |
| Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,876,556 | March 15, 2021 | February 28, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Ribosome Structure and Function | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,829,940 | April 1, 2016 | March 31, 2027 | NOLLER, HARRY F | reporter.nih.gov |
| Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,809,183 | August 1, 2015 | July 31, 2030 | LARSEN, MICHELLE H | reporter.nih.gov |
| Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,789,374 | September 15, 2019 | May 31, 2025 | YOON, CHRISTINA | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,731,271 | April 10, 2020 | March 31, 2023 | ALLAND, DAVID | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,694,016 | March 4, 2021 | February 28, 2027 | MAGEE, MATTHEW JAMES | reporter.nih.gov |
| Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHP | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,693,137 | May 1, 2021 | March 31, 2027 | LYON, CHRISTOPHER J | reporter.nih.gov |
| The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,655,506 | March 10, 2023 | February 29, 2028 | FARLEY, JASON EDWARD | reporter.nih.gov |
| Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,631,144 | March 4, 2019 | February 28, 2025 | SCANGA, CHARLES A. | reporter.nih.gov |
| Mechanisms of cough in Mycobacterium tuberculosis transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,611,276 | March 8, 2021 | February 28, 2026 | SHILOH, MICHAEL | reporter.nih.gov |
| Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,610,454 | August 5, 2021 | July 31, 2025 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| Molecular Analysis of Host Immune Response in Leprosy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,593,035 | January 1, 1991 | May 31, 2029 | MODLIN, ROBERT L | reporter.nih.gov |
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Defining adaptive immune responses to Mtb-infection and TB disease among young children with and without HIV-exposure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,527,794 | April 15, 2021 | March 31, 2027 | LANCIONI, CHRISTINA LOUISE | reporter.nih.gov |
| Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,492,579 | August 1, 2020 | May 31, 2026 | CHAISSON, RICHARD E. | reporter.nih.gov |
| Targeting TB transmission hotspots to find undiagnosed TB in South Africa: a genomic, geospatial and modeling study (TARGET- TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,433,190 | May 1, 2025 | April 30, 2027 | MATHEMA, BARUN | reporter.nih.gov |
| Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,397,377 | November 17, 2024 | November 16, 2025 | OLINGER, GENE GARRARD | reporter.nih.gov |
| Socio-spatial Networks and Tuberculosis Infection in Youth in Rural Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,369,946 | November 16, 2020 | October 31, 2026 | MARQUEZ, CARINA | reporter.nih.gov |
| M. tuberculosis exosome detection for pediatric TB diagnosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,323,600 | June 1, 2025 | May 31, 2027 | LACOURSE, SYLVIA | reporter.nih.gov |
| TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,322,837 | August 1, 2021 | July 31, 2026 | BOULWARE, DAVID R | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,466 | April 10, 2020 | March 31, 2026 | ALLAND, DAVID | reporter.nih.gov |
| Lesion-centric optimization of multidrug therapies for tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,301,434 | January 15, 2020 | December 31, 2025 | ALDRIDGE, BREE BEARDSLEY | reporter.nih.gov |
| Role of Ubiquitin Ligases and Deubiquitinases in Host Defense against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,278,392 | August 21, 2025 | July 31, 2029 | SHILOH, MICHAEL | reporter.nih.gov |
| Informing Drug Synergy: Investigating Mycobacterial Membrane Protein Structure and Function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,262,539 | August 1, 2025 | July 31, 2029 | REGO, ELIZABETH HESPER | reporter.nih.gov |
| Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,255,352 | September 16, 2020 | August 31, 2025 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,249,590 | March 10, 2020 | February 28, 2026 | SHERMAN, DAVID R | reporter.nih.gov |
| Video DOT and Economic Incentives to promote adherence to LTBI therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,246,780 | July 8, 2021 | June 30, 2027 | SHAH, MAUNANK | reporter.nih.gov |
| PROgression of Tuberculosis infECTion in young children living with and without HIV: the PROTECT study | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,235,332 | April 1, 2023 | March 31, 2028 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Novel Methods to Inform HIV/TB Clinical Trial Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,228,180 | September 1, 2011 | August 31, 2025 | REDDY, KRISHNA P | reporter.nih.gov |
| Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,198,798 | September 30, 2025 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| Dual Targeting of Mtb Resistance Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,194,513 | September 22, 2020 | August 31, 2025 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Elucidating the path to type I IFNs in TB infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,182,185 | April 1, 2021 | March 31, 2026 | BARCZAK, AMY K | reporter.nih.gov |
| An Enhanced Package of Care to Reduce Mortality in Persons with Advanced HIV Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,179,431 | August 23, 2021 | July 31, 2026 | RAJASINGHAM, RADHA | reporter.nih.gov |
| Biomarker Signatures of TB Infection in Young Children With and Without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,148 | April 28, 2023 | March 31, 2028 | SALGAME, PADMINI | reporter.nih.gov |
| Preclinical modeling to study Tuberculous Meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,172,738 | April 1, 2020 | March 31, 2026 | JAIN, SANJAY | reporter.nih.gov |
| Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,153,952 | September 1, 2013 | May 31, 2029 | BOULWARE, DAVID R | reporter.nih.gov |
| Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,153,883 | September 24, 2018 | October 31, 2028 | HEYSELL, SCOTT K | reporter.nih.gov |
| Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,145,850 | September 19, 2025 | August 31, 2029 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,139,781 | May 6, 2020 | April 30, 2026 | BRYSON, BRYAN DAVID | reporter.nih.gov |
| Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,136,573 | July 13, 2021 | June 30, 2025 | AUBE, JEFFREY | reporter.nih.gov |
| A New Approach to an Old Problem: Redesigning Latent Tuberculosis Screening and Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,126,853 | March 17, 2020 | February 28, 2026 | TARTOF, SARA | reporter.nih.gov |
| FEND-TB | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,089,360 | September 10, 2025 | August 31, 2030 | ELLNER, JERROLD J. | reporter.nih.gov |
| Tailoring modifications of polysaccharides in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,062,061 | September 17, 2021 | August 31, 2027 | JACKSON, MARY | reporter.nih.gov |
| Mechanisms of Innate Immune Evasion by Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,061,547 | January 1, 2017 | December 31, 2026 | PHILIPS, JENNIFER A | reporter.nih.gov |
| Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,053,206 | January 10, 2020 | December 31, 2025 | NAGAJYOTHI, JYOTHI FALGUNI | reporter.nih.gov |
| Assembly and export of mycobacterial lipoglycans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,040,802 | June 10, 2021 | May 31, 2027 | JACKSON, MARY | reporter.nih.gov |
| Enhancing cytotoxic lymphocytes in a TB vaccine strategy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,076 | February 25, 2022 | January 31, 2027 | FLYNN, JOANNE L. | reporter.nih.gov |
| Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,027,518 | March 17, 2020 | February 28, 2025 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Chemical Biological Discovery of Lipid Virulence Factors in the Major Bacterial Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,024,614 | June 22, 2022 | May 31, 2027 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,024,535 | July 1, 2020 | June 30, 2025 | JAIN, SANJAY | reporter.nih.gov |
| Dissecting the pathogenesis of HIV-TB Immune reconstitution inflammatory syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,018,989 | August 17, 2020 | July 31, 2026 | LIN, PHILANA LING | reporter.nih.gov |
| Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,016,918 | September 30, 2024 | September 29, 2025 | SUMNER, LOUISE | reporter.nih.gov |
| Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil Network | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,000,000 | January 2, 2023 | December 31, 2027 | STERLING, TIMOTHY R | reporter.nih.gov |
| Improving diagnostic sensitivity for difficult-to-lyse microbial samples with nanodroplet technology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,731 | August 3, 2020 | April 30, 2026 | KASOJI, SANDEEP | reporter.nih.gov |
| Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,164 | April 21, 2021 | July 31, 2025 | COONEY, CHRISTOPHER GERARD | reporter.nih.gov |
| Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,992,852 | December 13, 2019 | November 30, 2024 | HANNAN, THOMAS JOSEPH | reporter.nih.gov |
| Teixobactin Development for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,988,753 | September 1, 2022 | August 31, 2025 | HUGHES, DALLAS | reporter.nih.gov |
| The role of FENDRR in host defense against Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,963,619 | September 21, 2022 | July 31, 2027 | CHENG, YONG | reporter.nih.gov |
| Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,952,078 | March 1, 2025 | February 28, 2027 | METCALFE, JOHN ZAPATA | reporter.nih.gov |
| Understanding resistance and tolerance to nitroimidazoles in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,944,529 | July 23, 2025 | June 30, 2029 | SCHNAPPINGER, DIRK | reporter.nih.gov |
| Investigating bacterial contributions to TB treatment response: a focus on in-host pathogen dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,943,133 | September 22, 2020 | August 31, 2025 | FARHAT, MAHA | reporter.nih.gov |
| Characterization of the nutrient assimilation pathways in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,936,418 | November 19, 2020 | October 31, 2025 | VANDERVEN, BRIAN C | reporter.nih.gov |
| Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,922,220 | September 3, 2025 | August 31, 2029 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Targeting Membrane Transport Steps in Cell Envelope Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,914,356 | May 21, 2020 | July 31, 2025 | KAHNE, DANIEL | reporter.nih.gov |
| Translational approaches to improve understanding and outcome in Tuberculous meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,879,850 | March 19, 2020 | March 31, 2026 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,868,530 | August 9, 2021 | July 31, 2025 | SHERMAN, DAVID R | reporter.nih.gov |
| Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistant TB therapy in a high HIV prevalence setting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,868,143 | December 26, 2019 | November 30, 2026 | BRUST, JAMES C M | reporter.nih.gov |
| Mechanisms of CD4 T cell help to myeloid cells in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,863,501 | August 1, 2025 | July 31, 2029 | BOLD, TYLER DALLAS | reporter.nih.gov |
| Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,850,504 | May 1, 2020 | April 30, 2026 | FRANKE, MOLLY FORREST | reporter.nih.gov |
| Design, Syntheses and Studies of Novel Antituberculosis Agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,840,145 | September 1, 2021 | August 31, 2026 | MILLER, MARVIN J | reporter.nih.gov |
| Differentially Culturable Tubercle Bacteria: The missing link in TB Transmission? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,838,851 | September 1, 2019 | August 31, 2025 | KANA, BAVESH DAVANDRA | reporter.nih.gov |
| HIV, gestational diabetes and TB in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,837,523 | July 15, 2022 | June 30, 2027 | MATHAD, JYOTI S | reporter.nih.gov |
| Network Dissection of Host-Pathogen Interactions in Mycobacterium tuberculosis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,827,500 | August 3, 2021 | July 31, 2026 | MA, SHUYI | reporter.nih.gov |
| Aerobiology, immunology, and Mycobacterium tuberculosis transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,825,908 | July 10, 2020 | June 30, 2025 | HORNE, DAVID J. | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery: Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,815,378 | September 30, 2019 | September 29, 2023 | PETERS, BJOERN | reporter.nih.gov |
| Chemical Probes of Mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,777,928 | February 1, 2017 | March 31, 2027 | KIESSLING, LAURA L | reporter.nih.gov |
| Necrosis in Pulmonary TB granulomas: dynamics, mechanisms, and therapies | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,774,492 | May 1, 2016 | February 28, 2026 | KRAMNIK, IGOR | reporter.nih.gov |
| Undetected Drug resistance and Tolerance in lesions of recurrent TB | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,771,822 | July 1, 2022 | June 30, 2027 | VALAFAR, FARAMARZ | reporter.nih.gov |
| Multi-level and Intersectional Stigma and other Social Determinant Effects on TB Case Detection, Care, and Treatment Outcomes: The MISSED TB Outcomes Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,767,378 | December 1, 2020 | November 30, 2026 | MEDINA-MARINO, ANDREW | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,754,890 | April 1, 2015 | September 1, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Linking Human TB Genetic Susceptibility Loci to Granuloma Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,749,788 | January 11, 2022 | December 31, 2026 | TOBIN, DAVID M. | reporter.nih.gov |
| Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,735,126 | April 1, 2021 | March 31, 2027 | VAN DER HEIJDEN, YURI F. | reporter.nih.gov |
| Adjuvant Development in the context of a vaccine to protect against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,722,493 | September 30, 2018 | September 29, 2023 | PETROVSKY, NIKOLAI | reporter.nih.gov |
| Generation of a Complete Set of Precise Null Bar-Coded Deletion Mutants of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,711,266 | September 14, 2017 | June 30, 2028 | JACOBS, WILLIAM ROBERT | reporter.nih.gov |
| Hybrid trial for Alcohol reduction among people with TB and HIV in India (HATHI) | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $2,710,996 | September 5, 2020 | May 31, 2025 | GUPTA, AMITA | reporter.nih.gov |
| Regulation of innate immunity by self-adjuvated MRNA vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,710,680 | August 12, 2025 | May 31, 2029 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Development of Inhaled CPZEN-45 For Tuberculosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,694,338 | March 1, 2019 | February 28, 2025 | SEVERYNSE-STEVENS, DIANA M | reporter.nih.gov |
| Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,692,722 | April 6, 2023 | August 8, 2025 | TORRELLES, JORDI B | reporter.nih.gov |
| Targeted cell-depleting immunotherapy for TB and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,691,184 | February 25, 2020 | January 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Pattern Recognition Receptors and Autophagy in Mtb Control in AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,686,330 | April 1, 1998 | March 31, 2028 | DERETIC, VOJO P | reporter.nih.gov |
| Early and accurate diagnosis of pulmonary and extrapulmonary tuberculosis in all patient groups using a circulating pathogen-derived antigen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,685,056 | August 25, 2021 | July 31, 2025 | TOMBLER, THOMAS W | reporter.nih.gov |
| Th9 cells and protective TB immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,670,376 | March 9, 2022 | February 28, 2027 | HOFT, DANIEL F. | reporter.nih.gov |
| Characterizing Macrophages as "Hide-Outs" for Chronic Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,655,871 | August 1, 2021 | July 31, 2027 | CLAYTON, KIERA L. | reporter.nih.gov |
| Mycobacterial DNA repair and mutagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,655,624 | February 1, 2005 | May 31, 2025 | GLICKMAN, MICHAEL S | reporter.nih.gov |
| Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness. | NIH | National Cancer Institute | 2021 to 2025 | $2,653,805 | September 15, 2021 | August 31, 2027 | GOLUB, JONATHAN E. | reporter.nih.gov |
| Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,651,462 | February 13, 2019 | January 31, 2025 | POWIS, KATHLEEN | reporter.nih.gov |
| A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,649,150 | September 18, 2020 | June 30, 2025 | HEYSELL, SCOTT K | reporter.nih.gov |
| Detecting pathogen and host factors on extracellular vesicles for pediatric TB diagnosis and management | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,633,435 | March 17, 2017 | June 30, 2028 | HU, TONY Y. | reporter.nih.gov |
| Lung immune function in human TB infection and its perturbation by HIV-1. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,627,712 | June 4, 2020 | May 31, 2025 | RUSSELL, DAVID G | reporter.nih.gov |
| Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes (Clinical and public health approaches to tobacco cessation in South Africa supplement) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,627,377 | September 1, 2020 | July 31, 2025 | REDDY, KRISHNA P | reporter.nih.gov |
| Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,623,121 | June 17, 2019 | May 31, 2025 | STERLING, TIMOTHY R | reporter.nih.gov |
| Using the Mycobacterium tuberculosis Genome to Predict Tuberculosis Pathology, Drug Resistance Acquisition and Identify Community Transmission Sites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,610,785 | April 15, 2020 | March 31, 2026 | GILMAN, ROBERT H | reporter.nih.gov |
| Dynamics of the cellular and molecular architecture of human pulmonary TB granulomas | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,600,654 | February 10, 2022 | January 31, 2027 | MODLIN, ROBERT L | reporter.nih.gov |
| Who are the Ultra-positive, culture-negative? Understanding the trajectories of individuals in Uganda with trace M. tuberculosis nucleic acid in sputum | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,597,618 | September 15, 2020 | August 31, 2025 | KENDALL, EMILY A | reporter.nih.gov |
| Strategies for tuberculosis control in prisons | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,581,087 | March 1, 2017 | February 29, 2028 | ANDREWS, JASON RANDOLPH | reporter.nih.gov |
| ULTIMATE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,579,550 | April 1, 2019 | March 31, 2024 | VAN CREVEL, REINOUT | reporter.nih.gov |
| Improved understanding of TB transmission by accounting for within-host heterogeneity of M. tuberculosis: A population-based molecular epidemiology study in a high HIV prevalent setting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,579,446 | February 7, 2020 | January 31, 2026 | SHIN, SANGHYUK SAM | reporter.nih.gov |
| Functional dynamics of TB granuloma architecture | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,566,261 | March 18, 2022 | February 28, 2027 | ERNST, JOEL D. | reporter.nih.gov |
| Lung-Protective Mechanisms of Metformin in TB | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,548,097 | February 5, 2021 | January 31, 2026 | KORNFELD, HARDY | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,545,675 | September 30, 2025 | September 29, 2026 | ALTIN, JOHN | reporter.nih.gov |
| Genome-Wide Dissection of Mendelian Susceptibility to Mycobacterial Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,542,500 | May 1, 2011 | April 30, 2027 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,540,587 | July 1, 2023 | June 30, 2028 | ERNST, JOEL D. | reporter.nih.gov |
| Sirtuins and Host Metabolism in TB Pathogenesis and Treatment | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,537,961 | April 15, 2021 | March 31, 2026 | KORNFELD, HARDY | reporter.nih.gov |
| Sirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,534,348 | August 1, 2024 | July 31, 2029 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| B12 Trafficking and Inherited Defects | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,532,174 | February 1, 1998 | January 31, 2028 | BANERJEE, RUMA V | reporter.nih.gov |
| The role of tyrosine metabolism in tuberculosis pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,518,656 | February 21, 2023 | January 31, 2028 | SULIMAN, SARA | reporter.nih.gov |
| Minimally Invasive Tissues Sampling to Evaluate HIV-associated Meningitis in Zambia | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,516,061 | June 15, 2022 | April 30, 2027 | SIDDIQI, OMAR KHALIK | reporter.nih.gov |
| MmpL3 as a target for novel anti-TB agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,515,476 | June 15, 2015 | March 31, 2026 | JACKSON, MARY | reporter.nih.gov |
| Excess cardiovascular inflammation in TB and HIV: EXFIN-TB | NIH | National Heart, Lung, and Blood Institute | 2025 | $2,513,201 | September 1, 2025 | August 31, 2029 | BISSON, GREGORY P. | reporter.nih.gov |
| Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,508,444 | August 3, 2020 | July 31, 2025 | NAIDOO, ANUSHKA | reporter.nih.gov |
| The effect of HIV exposure and infection on immunity to TB in children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,482,220 | January 1, 2019 | December 31, 2025 | JOHN-STEWART, GRACE C. | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,475,623 | May 10, 2024 | November 9, 2025 | FOTOUHI, NADER | reporter.nih.gov |
| Chemical genetics of M. tuberculosis DosRST signaling and persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,472,195 | September 22, 2020 | August 31, 2025 | ABRAMOVITCH, ROBERT B | reporter.nih.gov |
| Novel and Optimized Diagnostics for Pediatric TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,461,700 | May 7, 2020 | April 30, 2023 | ELLNER, JERROLD J. | reporter.nih.gov |
| Novel and Optimized Diagnostics for Pediatric TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,451,069 | May 7, 2020 | April 30, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| TB Aftermath | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,441,657 | June 1, 2020 | May 31, 2027 | GOLUB, JONATHAN E. | reporter.nih.gov |
| Genetic and hormonal mechanisms mediating sex differences in TB and TB-HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,441,514 | February 1, 2022 | January 31, 2028 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Identifying correlates of risk for future tuberculosis disease progression in children (INTREPID) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,440,431 | May 1, 2025 | April 30, 2028 | SEDDON, JAMES ALEXANDER | reporter.nih.gov |
| T cell responses to CD1-restricted lipids in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,419,239 | March 1, 2001 | February 28, 2026 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Host blood biomarkers for the diagnosis prognosis and treatment response of childhood TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,409,972 | February 20, 2019 | January 31, 2025 | HATHERILL, MARK | reporter.nih.gov |
| M. tuberculosis carbon metabolism during infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,408,722 | June 2, 2023 | May 31, 2028 | EHRT, SABINE | reporter.nih.gov |
| Manipulation of the host cell inflammasome by Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,406,844 | June 8, 2021 | May 31, 2027 | BRIKEN, VOLKER | reporter.nih.gov |
| Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,406,319 | December 1, 2017 | November 30, 2025 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,404,290 | July 20, 2023 | June 30, 2028 | SCANGA, CHARLES A. | reporter.nih.gov |
| Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,399,976 | April 1, 2018 | March 31, 2024 | HAWN, THOMAS R | reporter.nih.gov |
| Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,391,699 | May 16, 2018 | April 30, 2025 | MEHRA, SMRITI | reporter.nih.gov |
| PROTEASOMAL REGULATION AND PROTEIN QUALITY CONTROL IN M. TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,390,710 | December 1, 2010 | March 31, 2026 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| A Global Research Resource for Human Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,389,377 | June 18, 2024 | May 31, 2029 | STEYN, ADRIE JC | reporter.nih.gov |
| A Preclinical Program for Targeting Mycobacterium tuberculosis KasA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,385,783 | August 10, 2021 | July 31, 2026 | FREUNDLICH, JOEL STEPHEN | reporter.nih.gov |
| Development of a Self Inactivating, Highly Effective TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,381,016 | February 6, 2019 | January 31, 2024 | FLYNN, JOANNE L. | reporter.nih.gov |
| Chemical Mycobateriology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,380,609 | September 1, 2025 | August 31, 2026 | BERTOZZI, CAROLYN | reporter.nih.gov |
| Bacterial disruption of neuroimmune pathways in a transparent brain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,370,000 | September 15, 2021 | August 31, 2026 | MADIGAN, CRESSIDA ARIANNA | reporter.nih.gov |
| Molecular Genetic Analysis of Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,368,749 | December 1, 1988 | August 31, 2028 | JACOBS, WILLIAM ROBERT | reporter.nih.gov |
| RNA modification and antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,361,815 | May 1, 2010 | April 30, 2026 | CONN, GRAEME L | reporter.nih.gov |
| Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,354,572 | August 7, 2019 | July 31, 2030 | SCHLESINGER, LARRY S. | reporter.nih.gov |
| Targeting Biotin Metabolism in Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,339,589 | January 15, 2019 | December 30, 2023 | ALDRICH, COURTNEY C | reporter.nih.gov |
| Cavity and Granuloma Oriented Inflammation and Tissue Pharmacokinetics in Pulmonary Tuberculosis (COOK TB) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,339,351 | February 9, 2023 | January 31, 2028 | KEMPKER, RUSSELL RYAN | reporter.nih.gov |
| Characteristics and protective efficacy of human antibodies against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,338,122 | July 1, 2019 | June 30, 2025 | ACHKAR, JACQUELINE MICHELE | reporter.nih.gov |
| Hypoxia, tuberculosis, and T cell dysfunction | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,330,835 | June 1, 2023 | May 31, 2028 | BEHAR, SAMUEL M | reporter.nih.gov |
| Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,326,177 | March 10, 2022 | February 28, 2027 | O'DONNELL, MAX | reporter.nih.gov |
| Identifying TB transmitters in high TB/HIV burdened communities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,325,597 | September 5, 2019 | August 31, 2025 | WOOD, ROBIN | reporter.nih.gov |
| Macrophage Reprogramming During Granuloma Formation in the Zebrafish | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,325,311 | March 3, 2017 | February 28, 2027 | TOBIN, DAVID M. | reporter.nih.gov |
| One-carbon metabolism and immune cell function in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,323,713 | August 2, 2023 | July 31, 2027 | SHI, LANBO | reporter.nih.gov |
| Mechanisms of efficient control of Mycobacterium tuberculosis in the lungs prior to granuloma | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,322,288 | July 9, 2024 | May 31, 2029 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Durability of systemic and lung immune correlates of BCG-induced protection against M. tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,311,437 | August 11, 2020 | July 31, 2026 | NEMES, ELISA | reporter.nih.gov |
| Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,302,219 | December 15, 2010 | July 31, 2026 | KHADER, SHABAANA A. | reporter.nih.gov |
| Genetic dissection of angiogenesis during mycobacterial infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,299,646 | February 15, 2017 | January 31, 2027 | TOBIN, DAVID M. | reporter.nih.gov |
| Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,298,018 | December 15, 2017 | November 30, 2023 | MALLEY, RICHARD | reporter.nih.gov |
| Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,278,505 | April 3, 2023 | March 31, 2028 | O'DONNELL, MAX | reporter.nih.gov |
| Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,277,213 | November 25, 2022 | October 31, 2027 | MATHEMA, BARUN | reporter.nih.gov |
| Coronary Atherosclerosis and Immune Activation in HIV and Tuberculosis Infection | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,274,138 | August 2, 2022 | July 31, 2027 | HUAMAN JOO, MOISES ARTURO | reporter.nih.gov |
| The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,264,154 | March 10, 2021 | February 28, 2026 | BAUGHN, ANTHONY D | reporter.nih.gov |
| Tuberculosis Immunopathogenesis During Superinfection with SARS-CoV2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,255,725 | May 15, 2023 | April 30, 2028 | TALAAT, ADEL M | reporter.nih.gov |
| Rapid Detection of TB from Blood using Cell-Free DNA and CRISPR | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,253,957 | July 17, 2023 | June 30, 2027 | RODWELL, TIMOTHY CHARLES | reporter.nih.gov |
| New potent orally bioavailable nitro-containing compounds to treat mycobacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,248,740 | July 7, 2025 | June 30, 2028 | ABRAMOVITCH, ROBERT B | reporter.nih.gov |
| Prevent TB: Application of choice architecture to implement TB preventive therapy in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,248,070 | February 28, 2020 | January 31, 2027 | HOFFMANN, CHRISTOPHER J | reporter.nih.gov |
| Mechanisms of vitamin A-dependent risk for tuberculosis progression and prevention | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,246,313 | June 15, 2023 | May 31, 2028 | PODELL, BRENDAN | reporter.nih.gov |
| When are in-person HIV services worth the risk of COVID-19 and other communicable illnesses? Optimizing choices when virtual services are less effective | NIH | National Institute of Mental Health | 2022 to 2024 | $2,244,785 | September 1, 2022 | July 31, 2027 | BERSHTEYN, ANNA | reporter.nih.gov |
| A nanopore biosensor for leveling Mtb antigens in blood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,238,457 | June 15, 2022 | May 31, 2028 | LYON, CHRISTOPHER J | reporter.nih.gov |
| Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,236,678 | July 13, 2023 | June 30, 2028 | ABRAMOVITCH, ROBERT B | reporter.nih.gov |
| Elucidating the mechanisms and consequences of MDSC-regulated immunity in TB | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,236,002 | July 22, 2022 | June 30, 2027 | MATTILA, JOSHUA T. | reporter.nih.gov |
| Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trial | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,225,984 | August 15, 2017 | November 30, 2026 | KENDALL, EMILY A | reporter.nih.gov |
| Automated Sequencing for Culture-free Diagnosis of Drug Resistant TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,220,441 | April 17, 2023 | March 31, 2028 | RODWELL, TIMOTHY CHARLES | reporter.nih.gov |
| Autophagy Against Tuberculosis and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,218,437 | March 1, 2014 | February 28, 2026 | DERETIC, VOJO P | reporter.nih.gov |
| Identifying Optimal Treatment Strategies for Tuberculosis Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,217,092 | January 16, 2019 | December 31, 2024 | SAVIC, RADOJKA | reporter.nih.gov |
| Toxin secretion and trafficking by Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,216,121 | July 17, 2023 | June 30, 2027 | NIEDERWEIS, MICHAEL | reporter.nih.gov |
| Post-TB epigenetic scars' impact on long-term inflammation, immunity and mortality | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,213,177 | July 1, 2023 | June 30, 2028 | DINARDO, ANDREW R | reporter.nih.gov |
| Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,202,681 | August 11, 2023 | July 31, 2028 | HUANG, ZHEN | reporter.nih.gov |
| Etiology of Persistent Microalbuminuria in Nigeria | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,202,068 | July 1, 2021 | May 31, 2026 | WESTER, C. WILLIAM | reporter.nih.gov |
| An Antigen-Detection Blood Test for Pulmonary Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,200,977 | July 3, 2019 | June 30, 2025 | CATANZARO, ANTONINO | reporter.nih.gov |
| Integrating genomic and spatial approaches for targeted control of HIV-associated tuberculosis epidemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,197,125 | August 1, 2020 | July 31, 2025 | COHEN, THEODORE H | reporter.nih.gov |
| Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,180,842 | August 1, 2019 | July 31, 2025 | JACOBSON, KAREN R | reporter.nih.gov |
| Bacterial and Molecular Determinants of Mycobacterial Impermeability | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,177,331 | August 2, 2023 | July 31, 2028 | PIRES, MARCOS M. | reporter.nih.gov |
| An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,172,351 | September 1, 2025 | August 31, 2028 | FARHAT, MAHA | reporter.nih.gov |
| INTERCEPT | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,147,632 | January 1, 2022 | December 31, 2026 | VAN CREVEL, REINOUT | reporter.nih.gov |
| Diagnostic Innovations for Pediatric Tuberculosis in Bolivia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,139,484 | June 1, 2025 | May 31, 2028 | OBERHELMAN, RICHARD A | reporter.nih.gov |
| Optimization of Atypical Antimycobacterial Carbapenem Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,139,287 | July 19, 2023 | June 30, 2028 | BUYNAK, JOHN D | reporter.nih.gov |
| A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,133,601 | July 7, 2023 | June 30, 2028 | METCALFE, JOHN ZAPATA | reporter.nih.gov |
| Single-cell factors of tuberculosis drug tolerance during adaptation to environmental stressors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,121,678 | April 1, 2020 | March 31, 2025 | ALDRIDGE, BREE BEARDSLEY | reporter.nih.gov |
| Regulators of IFN-gamma responses during Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,095,936 | July 6, 2022 | June 30, 2027 | OLIVE, ANDREW | reporter.nih.gov |
| Human-centered Design and Communities of Practice to Improve Delivery of Home-based TB Contact Investigation in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,074,247 | June 17, 2013 | December 31, 2024 | DAVIS, JOHN LUCIAN | reporter.nih.gov |
| Defining the antibody interface between Mycobacterium tuberculosis and host immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,063,021 | September 23, 2021 | August 31, 2027 | LU, LENETTE | reporter.nih.gov |
| Tuberculosis Research and Mentorship Program (TB RAMP II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,053,078 | September 12, 2025 | August 31, 2030 | FAIR, ELIZABETH | reporter.nih.gov |
| Redefining Tuberculosis Meningitis with Metagenomics and Host Transciptomics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,043,168 | March 11, 2019 | February 28, 2025 | WILSON, MICHAEL R | reporter.nih.gov |
| Investigating alveolar macrophages in PLWH as targets for HIV persistence, residual inflammation and immune activation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,041,080 | July 19, 2024 | June 30, 2029 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| The regulation and functions of Group 1 CD1-restricted T cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,036,996 | September 20, 2023 | July 31, 2028 | WANG, CHYUNG-RU | reporter.nih.gov |
| Long Acting Injectable Depots for TB Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,013,687 | June 22, 2021 | May 31, 2024 | STAYTON, PATRICK S. | reporter.nih.gov |
| Childhood ‘Omics’ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,008,838 | April 22, 2020 | December 31, 2022 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Targeting trans-translation to kill M. tuberculosis non-replicating persister cells | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,004,012 | November 1, 2021 | April 30, 2024 | KEILER, KENNETH C | reporter.nih.gov |
| Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,998,000 | April 7, 2023 | March 31, 2028 | TORNHEIM, JEFFREY | reporter.nih.gov |
| Seattle-Lausanne Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,995,056 | February 1, 2007 | March 31, 2022 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| Optimal targeting for individual and population-level TB prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,986,197 | December 5, 2019 | November 30, 2025 | MENZIES, NICOLAS A | reporter.nih.gov |
| Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,956,687 | June 13, 2024 | April 30, 2029 | COLER, RHEA N | reporter.nih.gov |
| Interplay of M. tuberculosis trehalose metabolism and its pathogenesis and drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,953,308 | March 16, 2023 | February 28, 2027 | EOH, HYUNGJIN | reporter.nih.gov |
| Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,942,637 | April 4, 2023 | March 31, 2028 | KATO-MAEDA, MIDORI | reporter.nih.gov |
| Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,927,436 | November 18, 2022 | October 31, 2027 | BERNEY, MICHAEL | reporter.nih.gov |
| Parallel phenotyping to dissect genetic determinants of bacterial strain diversity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,920,876 | August 9, 2022 | July 31, 2027 | CAREY, ALLISON | reporter.nih.gov |
| The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,904,986 | February 25, 2019 | January 31, 2024 | SCHACKER, TIMOTHY W | reporter.nih.gov |
| Molecular Mechanisms of Transcription Initiation and DNA Repair | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,894,422 | March 1, 2022 | February 28, 2027 | GALBURT, ERIC A | reporter.nih.gov |
| Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,893,366 | November 13, 2018 | October 31, 2025 | BERNEY, MICHAEL | reporter.nih.gov |
| Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,886,759 | August 23, 2016 | May 31, 2026 | BEDFORD, TREVOR BC | reporter.nih.gov |
| Targeting NETosis for the Treatment of Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,886,199 | June 1, 2023 | May 31, 2028 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,878,234 | July 1, 2021 | June 30, 2027 | RODRIGUEZ, GLORIA MARCELA | reporter.nih.gov |
| Heme and hemoglobin utilization by Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,878,218 | January 1, 2019 | December 31, 2024 | NIEDERWEIS, MICHAEL | reporter.nih.gov |
| Mechanisms and Consequences of Mycobacterial N-terminal Protein Acetylation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,878,000 | May 10, 2013 | August 31, 2025 | CHAMPION, PATRICIA A | reporter.nih.gov |
| SAIA-TB: Using the Systems Analysis and Improvement Approach (SAIA) to prevent TB in rural South Africa | NIH | National Institute of Nursing Research | 2023 to 2025 | $1,875,237 | May 12, 2023 | February 29, 2028 | VAN DE WATER, BRITTNEY JAYNE | reporter.nih.gov |
| Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,866,727 | March 1, 2024 | January 31, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| New anti-tubercular agents targeting intracellular bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,866,467 | June 21, 2024 | January 31, 2026 | PARISH, TANYA | reporter.nih.gov |
| The Effectiveness and Cost-Effectiveness of Implementing Evidence-Based Depression Treatment within the TB Care Platform in South Africa: A Hybrid Effectiveness-Implementation Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,844,087 | September 1, 2025 | August 31, 2028 | SWEETLAND, ANNIKA CLAIRE | reporter.nih.gov |
| TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,841,700 | September 1, 2023 | August 31, 2028 | GOLUB, JONATHAN E. | reporter.nih.gov |
| Molecular mechanisms of host cell escape by Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,839,756 | January 10, 2019 | June 30, 2025 | BRIKEN, VOLKER | reporter.nih.gov |
| Drifting to victory: resolving the paradox of M. tuberculosis evolution | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,839,296 | June 15, 2015 | May 31, 2026 | PEPPERELL, CAITLIN S | reporter.nih.gov |
| Automated lung sound analysis to improve the clinical diagnosis of pulmonary tuberculosis in children | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,836,717 | September 15, 2023 | August 31, 2028 | JAGANATH, DEVAN | reporter.nih.gov |
| Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,831,148 | September 1, 2022 | November 30, 2025 | SLAYDEN, RICHARD | reporter.nih.gov |
| Personal Respiratory Isolation System for Safe Transport and Treatment of Patients with Highly Transmissible Infectious Diseases | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,828,885 | September 18, 2024 | March 31, 2026 | KOTA, SRIDHAR | reporter.nih.gov |
| Maximizing Investigators' Research Award (R35) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,821,876 | June 1, 2021 | May 31, 2026 | WHITE, LAURA FORSBERG | reporter.nih.gov |
| Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,820,801 | June 21, 2024 | April 30, 2029 | MEHRA, SMRITI | reporter.nih.gov |
| Molecular mechanisms of modular nuclease domains | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,812,290 | September 15, 2021 | August 31, 2026 | MANHART, CAROL M | reporter.nih.gov |
| Functional exploration of a deep Mycobacterium tuberculosis phosphoproteome | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,806,530 | February 3, 2023 | January 31, 2028 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,806,210 | June 21, 2022 | May 31, 2027 | BAHR, NATHAN | reporter.nih.gov |
| A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,803,446 | December 1, 2017 | November 30, 2023 | MORTENSEN, RASMUS SKAARUP | reporter.nih.gov |
| Targeting trained immunity and Th1/Th17 axis with combination adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,799,999 | July 26, 2021 | April 30, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Enhancing Pediatric Diagnosis of Tuberculosis with FLOW Technology | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $1,781,357 | May 10, 2022 | November 30, 2024 | MULLINS, BRIANNA | reporter.nih.gov |
| Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,779,708 | July 6, 2020 | June 30, 2025 | KHADER, SHABAANA A. | reporter.nih.gov |
| Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,778,326 | June 25, 2021 | June 30, 2027 | NUERMBERGER, ERIC L | reporter.nih.gov |
| Multivalent DNA vaccine-mediated protection against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,773,692 | November 23, 2017 | October 31, 2024 | WEINER, DAVID B. | reporter.nih.gov |
| A micronized electrostatic precipitator for next-generation respiratory protection against pathogenic aerosols | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,772,894 | August 17, 2023 | July 31, 2025 | HENLEY, JULIAN | reporter.nih.gov |
| Type I IFN-dependent and independent contributions to the outcomes of early innate immune cell interactions during HIV/TB co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,772,038 | July 3, 2024 | June 30, 2029 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Harnessing activated CD4 T cells to define new mechanisms of protection in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,770,744 | July 1, 2023 | June 30, 2028 | BOLD, TYLER DALLAS | reporter.nih.gov |
| Innovative contact tracing strategies for detecting TB in mobile rural and urban South African populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,765,691 | August 7, 2019 | July 31, 2025 | DOWDY, DAVID WESLEY | reporter.nih.gov |
| Role of IL-17 Cytokine Networks in TB Relapse Due to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,765,428 | June 21, 2019 | May 31, 2025 | ENDSLEY, JANICE J | reporter.nih.gov |
| Transporter function of the Mycobacterium tuberculosis PE/PPE proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,765,004 | February 6, 2024 | December 31, 2028 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Targeting protein secretion in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,763,806 | March 1, 2024 | January 31, 2026 | PARISH, TANYA | reporter.nih.gov |
| Optimizing vaccine science to improve the outcome of tuberculosis treatment | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,751,227 | June 17, 2021 | May 31, 2027 | SUBBIAN, SELVAKUMAR | reporter.nih.gov |
| Alternative Ribosomes & Antibiotic Tolerance in Mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,747,655 | June 1, 2017 | July 31, 2028 | OJHA, ANIL KUMAR | reporter.nih.gov |
| SigH based attenuated, efficacious Mtb vaccines to protect against lethal TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,745,052 | May 17, 2018 | April 30, 2025 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Mycobacterium tuberculosis environmental signal integration: single cell in vivo understanding of its influence on infection heterogeneity and treatment efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,740,661 | September 18, 2019 | August 31, 2025 | TAN, SHUMIN | reporter.nih.gov |
| Understanding and addressing geographic barriers to accessing TB services in a high-burden urban setting | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,737,469 | February 1, 2023 | January 31, 2028 | JENKINS, HELEN E. | reporter.nih.gov |
| Immune and metabolic dysfunction during aging in human cohorts | NIH | National Institute on Aging | 2022 to 2024 | $1,732,734 | September 30, 2022 | May 31, 2026 | RESTREPO, BLANCA I | reporter.nih.gov |
| Mitochondria as crucial regulators of innate immune outcomes during Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,731,677 | June 10, 2021 | July 31, 2024 | WATSON, ROBERT OWEN | reporter.nih.gov |
| Immune correlates of LTBI in HIV-exposed infants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,724,753 | January 5, 2019 | December 31, 2025 | PAHWA, SAVITA | reporter.nih.gov |
| Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,723,189 | June 25, 2021 | May 31, 2024 | NUERMBERGER, ERIC L | reporter.nih.gov |
| Biomimetic Peptide Aerosols for Rapid Clearance of Pulmonary MDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,718,155 | November 19, 2021 | October 31, 2026 | MEDINA, SCOTT HAMMOND | reporter.nih.gov |
| Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,715,089 | April 14, 2020 | March 31, 2025 | PINTER, ABRAHAM | reporter.nih.gov |
| Understanding ischemia in children with tuberculous meningitis (iThemba) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $1,692,676 | August 1, 2022 | May 31, 2027 | SEDDON, JAMES ALEXANDER | reporter.nih.gov |
| The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,687,352 | January 16, 2020 | December 31, 2026 | CHAN, JOHN R. | reporter.nih.gov |
| Siyakhula: Growing HIV/TB Research Knowledge for Growing Healthy Kids in Eswatini | NIH | Fogarty International Center | 2021 to 2025 | $1,686,671 | July 12, 2021 | March 31, 2027 | MANDALAKAS, ANNA M | reporter.nih.gov |
| Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,684,821 | January 2, 2024 | December 31, 2026 | SHI, WANLIANG | reporter.nih.gov |
| A Novel Th17-inducing Mucosal Vaccine for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,676,215 | September 9, 2020 | September 2, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Evaluating the Role of L,D-Transpeptidases in Mycobacterial Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,659,285 | June 18, 2020 | November 30, 2026 | BEATTY, KIMBERLY ELIZABETH | reporter.nih.gov |
| Short-course rifapentine for TB prevention for all: clinical pharmacology matters | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,657,415 | August 7, 2024 | June 30, 2029 | DOOLEY, KELLY E. | reporter.nih.gov |
| Molecular basis of antibiotic resilience in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,656,213 | June 1, 2024 | April 30, 2029 | FORTUNE, SARAH | reporter.nih.gov |
| "The molecular mechanisms of asymmetric cell division in mycobacteria." | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,655,369 | May 12, 2020 | April 30, 2025 | REGO, ELIZABETH HESPER | reporter.nih.gov |
| Perceived Laws and Infectious Disease Control Measures | NIH | National Institute of Nursing Research | 2023 to 2025 | $1,648,078 | August 23, 2023 | May 31, 2028 | GALLETLY, CAROL L | reporter.nih.gov |
| RNA Vaccine Innovations for TB: Targeting the Mucosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,632,094 | April 22, 2022 | September 30, 2025 | REED, STEVEN GREGORY | reporter.nih.gov |
| The role of lymphatic clearance in brain TB | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,623,071 | May 15, 2022 | April 30, 2027 | SANDOR, MATYAS | reporter.nih.gov |
| Advancing Innovative Next_generation Heterologous Vaccines Against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,615,572 | May 10, 2022 | April 30, 2026 | BEAMER, GILLIAN L | reporter.nih.gov |
| Investigating (di)terpenoid biosynthesis | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,611,459 | June 1, 2019 | November 30, 2024 | PETERS, REUBEN JOHN | reporter.nih.gov |
| Air Pollution Effects on Transmission of Mycobacterium tuberculosis in Urban Slum Community in Uganda | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,606,414 | September 15, 2012 | June 30, 2028 | SCHWANDER, STEPHAN K | reporter.nih.gov |
| Inhalational therapy with spectinamides within new regimens of TB therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,605,491 | July 5, 2024 | June 30, 2029 | GONZALEZ-JUARRERO, MERCEDES | reporter.nih.gov |
| A novel protein export chaperone of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,598,834 | January 3, 2020 | August 31, 2023 | BRAUNSTEIN, MIRIAM S. | reporter.nih.gov |
| TB/MDR-TB Research training and Capacity Strengthening for LMIC in Southeast Asia Phase II | NIH | Fogarty International Center | 2021 to 2025 | $1,596,256 | May 1, 2015 | February 28, 2027 | CHONGSUVIVATWONG, VIRASAKDI | reporter.nih.gov |
| The Role of Casual Contact and Migration in XDR TB Transmission in South Africa: a Geospatial, Genomic and Social Network Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,594,622 | January 17, 2018 | December 31, 2024 | SHAH, NIPPIE SARITA | reporter.nih.gov |
| Understanding the functional role of Myeloid Derived Suppressor cells in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,589,530 | July 6, 2020 | September 2, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Target based discovery of next generation pyrazinamide | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,586,105 | August 1, 2013 | May 31, 2023 | DICK, THOMAS | reporter.nih.gov |
| Type II alveolar epithelial cell-intrinsic IL-1 response in protective immunity against tuberculosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,576,457 | June 1, 2023 | May 31, 2027 | MISHRA, BIBHUTI BHUSAN | reporter.nih.gov |
| Foam cells as drug targets in tuberculosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,575,009 | August 1, 2019 | June 30, 2025 | GENNARO, MARIA LAURA | reporter.nih.gov |
| Mechanisms of IFNg-independent T cell and B cell-mediated protection in TB. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,569,789 | August 26, 2024 | June 30, 2029 | SALGAME, PADMINI | reporter.nih.gov |
| Synthetic Macrophage-inducible C-type lectin (Mincle) Agonists: Screening, Design, and Formulation in combination Th17 adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,563,776 | September 30, 2024 | September 29, 2029 | reporter.nih.gov | |
| Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,555,676 | February 26, 2024 | December 31, 2028 | ALLAND, DAVID | reporter.nih.gov |
| Control of cell wall synthesis and antibiotic tolerance in mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,552,748 | June 1, 2020 | May 31, 2026 | BOUTTE, CARA CHENEY | reporter.nih.gov |
| Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but resistant to Mtb Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,552,036 | July 1, 2018 | June 30, 2025 | GANDHI, NEEL RAJNIKANT | reporter.nih.gov |
| C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,551,336 | April 1, 2018 | April 30, 2025 | ENDSLEY, JANICE J | reporter.nih.gov |
| Metabolic regulation of macrophage function during M. tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,550,855 | April 10, 2015 | May 31, 2026 | STANLEY, SARAH A | reporter.nih.gov |
| Structure and function of ClpXP | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,548,938 | April 1, 2021 | March 31, 2026 | SAUER, ROBERT T | reporter.nih.gov |
| Understanding early macrophage-T cell interactions, SLAMF1, and immunity to TB | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,544,840 | July 1, 2024 | June 30, 2029 | PHILIPS, JENNIFER A | reporter.nih.gov |
| Trial of Metformin for TB/HIV Host-directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,542,974 | May 15, 2019 | April 30, 2026 | KORNFELD, HARDY | reporter.nih.gov |
| Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,532,717 | August 1, 2024 | July 31, 2029 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,526,635 | July 6, 2010 | February 29, 2024 | LEE, RICHARD E. | reporter.nih.gov |
| Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,522,818 | August 1, 2019 | July 31, 2025 | SCOTT, EVAN ALEXANDER | reporter.nih.gov |
| Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,521,407 | July 1, 2021 | June 30, 2026 | RODRIGUEZ, GLORIA MARCELA | reporter.nih.gov |
| Determining the role of sphingolipids in Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,520,395 | December 1, 2019 | November 30, 2025 | TAFESSE, FIKADU G. | reporter.nih.gov |
| Development of Drugs to Target Arginine Biosythesis in Mycobacterium tuberculosis | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,510,000 | April 22, 2021 | March 31, 2026 | TIWARI, SANGEETA | reporter.nih.gov |
| The PDIM paradox of M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,505,403 | February 1, 2023 | January 31, 2028 | BERNEY, MICHAEL | reporter.nih.gov |
| Development of novel penems for drug-resistant tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,504,818 | January 3, 2018 | December 31, 2024 | TOWNSEND, CRAIG ARTHUR | reporter.nih.gov |
| Ontogeny and metabolism of lung alveolar macrophages in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,503,349 | August 13, 2024 | July 31, 2029 | HUANG, LU | reporter.nih.gov |
| RAPID POINT OF CARE TESTS FOR TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,500,000 | August 12, 2021 | August 8, 2024 | ZHOU, YAN | reporter.nih.gov |
| INNOVATIVE PEDIATRIC ORAL FORMULATIONS FOR SECOND LINE TUBERCULOSIS DRUGS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,499,998 | September 3, 2021 | BRAUN, NIKOLAI | reporter.nih.gov | |
| Siderophore Inhibitors for Tuberculosis that Block Mycobactin Biosynthesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,499,516 | April 25, 2018 | March 31, 2023 | ALDRICH, COURTNEY C | reporter.nih.gov |
| Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,495,330 | September 24, 2018 | August 31, 2023 | NATHAN, CARL FRANCIS | reporter.nih.gov |
| HIV-associated Tuberculosis Training Program (HATTP) | NIH | Fogarty International Center | 2021 to 2025 | $1,494,206 | September 11, 2017 | April 30, 2027 | MEINTJES, GRAEME AYTON | reporter.nih.gov |
| Development of a highly-multiplexed CRISPR-based TB drug susceptibility test | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,493,529 | June 24, 2024 | May 31, 2029 | XIE, YINGDA LINDA | reporter.nih.gov |
| Ethiopia-Emory TB Research Training Program | NIH | Fogarty International Center | 2021 to 2025 | $1,483,720 | July 2, 2013 | December 31, 2028 | BLUMBERG, HENRY M | reporter.nih.gov |
| Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,480,554 | April 14, 2020 | March 31, 2026 | PINTER, ABRAHAM | reporter.nih.gov |
| Impact of TB coinfection on HIV reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,471,070 | December 11, 2023 | October 31, 2028 | DUPNIK, KATHRYN M | reporter.nih.gov |
| Identifying individuals at risk of progression to active tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,471,016 | February 22, 2018 | January 31, 2025 | CATANZARO, ANTONINO | reporter.nih.gov |
| Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,468,336 | January 19, 2018 | December 31, 2023 | METCALFE, JOHN ZAPATA | reporter.nih.gov |
| Phase II: Development of Low-Cost, Shelf-Stable Treatment for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,468,122 | September 15, 2023 | September 14, 2026 | WARNKEN, ZACHARY | reporter.nih.gov |
| Precision immunoprofiling to reveal diagnostic biomarkers of latent TB infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,466,090 | September 5, 2019 | August 31, 2025 | BAILEY, RYAN C | reporter.nih.gov |
| Immunometabolic Biomarkers to Advance TB Diagnosis and Treatment Monitoring | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,465,214 | April 16, 2024 | February 28, 2029 | COLLINS, JEFFREY M | reporter.nih.gov |
| Ultrasensitive detection of Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,461,934 | July 22, 2024 | June 30, 2029 | CIRILLO, JEFFREY D. | reporter.nih.gov |
| Understanding How the Ubiquitin Ligase CBL Regulates Innate Immune Responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,457,172 | September 19, 2019 | August 31, 2024 | PENN, BENNETT | reporter.nih.gov |
| Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,450,790 | September 19, 2025 | August 31, 2030 | GARCIA-PRATS, ANTHONY JOSEPH | reporter.nih.gov |
| Dissecting the genetic basis of protective immunity to tuberculosis in diverse hosts | NIH | National Institute of General Medical Sciences | 2021 | $1,449,000 | September 20, 2021 | August 31, 2024 | SMITH, CLARE MARGARET | reporter.nih.gov |
| CRISPR-TB for pediatric TB diagnosis and treatment response | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,446,304 | July 11, 2024 | May 31, 2029 | LACOURSE, SYLVIA | reporter.nih.gov |
| Tuberculosis & HIV Co-Infection Training Program in Kenya | NIH | Fogarty International Center | 2021 to 2025 | $1,438,418 | May 1, 2021 | March 31, 2027 | HAWN, THOMAS R | reporter.nih.gov |
| Interleukin-6 signaling, lung injury, and post-TB lung disease in TB-HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,430,251 | September 1, 2025 | August 31, 2029 | GUPTE, AKSHAY NITIN | reporter.nih.gov |
| Targeting mediators of oxidative stress to limit hyperinflammatory cell death modalities during Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,429,810 | June 24, 2024 | April 30, 2029 | WATSON, ROBERT OWEN | reporter.nih.gov |
| Novel Nanoparticle Respiratory Tract Mucosal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,426,482 | April 1, 2022 | March 31, 2025 | QUINN, FREDERICK D | reporter.nih.gov |
| Autophagy proteins in the immune response to Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,426,352 | November 7, 2018 | October 31, 2024 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Evolution, transmission, and control of drug-resistant tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,424,054 | July 17, 2024 | May 31, 2029 | GRUBAUGH, NATHAN DALE | reporter.nih.gov |
| Using Single Cell Biological Approaches to Understand CNS TB | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,419,875 | August 15, 2023 | May 31, 2029 | DULLA, CHRIS G | reporter.nih.gov |
| Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,418,806 | July 1, 2019 | June 30, 2024 | MANDALAKAS, ANNA M | reporter.nih.gov |
| Interaction of Mycobacterium tuberculosis with upper airway mucosal cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,414,352 | June 10, 2024 | May 31, 2029 | SHILOH, MICHAEL | reporter.nih.gov |
| Optimizing vaccine science to improve the outcome of tuberculosis treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,409,583 | June 17, 2021 | May 31, 2023 | SUBBIAN, SELVAKUMAR | reporter.nih.gov |
| Regulation of CD8+ T cell immunity to tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,409,160 | August 2, 2013 | April 30, 2024 | BEHAR, SAMUEL M | reporter.nih.gov |
| Investigating the role of liquid-liquid phase separation in the interaction between Mycobacterium tuberculosis and macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,398,216 | August 10, 2021 | July 31, 2026 | BELL, SAMANTHA LYNN | reporter.nih.gov |
| Target and Non-target Based Resistance to Bedaquiline in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,396,710 | April 20, 2020 | March 31, 2025 | MAKHADO, NDIVHU | reporter.nih.gov |
| Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,392,562 | April 1, 2022 | March 31, 2025 | LOVELL, JONATHAN F | reporter.nih.gov |
| Innate immune response of LTBI+HIV+ children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,390,281 | September 14, 2020 | February 18, 2024 | VANKAYALAPATI, RAMAKRISHNA | reporter.nih.gov |
| Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,389,906 | February 7, 2019 | January 31, 2024 | GLICKMAN, MICHAEL S | reporter.nih.gov |
| Nanoreactor beads for POC TB resistance testing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,388,246 | November 7, 2023 | October 31, 2028 | ALLAND, DAVID | reporter.nih.gov |
| Impact of HIV on the human alveolar environment drivingthe early events of Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,384,896 | August 16, 2024 | August 8, 2025 | TORRELLES, JORDI B | reporter.nih.gov |
| Structural characterization of MCE transport systems from Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,384,410 | February 3, 2023 | January 31, 2028 | BHABHA, GIRA | reporter.nih.gov |
| TB PrEP - Integrating HIV prevention with TB household contact evaluation | NIH | National Institute of Mental Health | 2024 to 2025 | $1,383,983 | September 9, 2024 | August 31, 2029 | ROSS, JENNIFER M | reporter.nih.gov |
| Molecular Genetic Analysis of Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,383,455 | December 1, 1988 | August 31, 2023 | JACOBS, WILLIAM ROBERT | reporter.nih.gov |
| When are in-person HIV services worth the risk of COVID-19 and other communicable illnesses? Optimizing choices when virtual services are less effective | NIH | National Institute of Mental Health | 2025 | $1,375,435 | September 1, 2022 | July 31, 2027 | BERSHTEYN, ANNA | reporter.nih.gov |
| A novel hyper-immunogenic low virulent BCG vaccine against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,373,187 | February 3, 2023 | April 20, 2025 | DHANDAYUTHAPANI, SUBRAMANIAN | reporter.nih.gov |
| How Mtb 3B-hydroxysteroid dehydrogenase accesses host cholesterol | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,367,738 | February 13, 2024 | December 31, 2028 | PHILIPS, JENNIFER A | reporter.nih.gov |
| High-throughput identification of common CD8+ T cell responses to SIV and M. tuberculosis in rhesus macaques | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $1,362,096 | September 1, 2014 | January 31, 2025 | O'CONNOR, DAVID H. | reporter.nih.gov |
| Addressing Research Gaps to Optimize Dolutegravir-based ART in Children and Adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,358,823 | August 5, 2024 | June 30, 2029 | KWARA, AWEWURA JACOB | reporter.nih.gov |
| Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,355,786 | June 15, 2018 | May 31, 2024 | LEWINSOHN, DAVID M. | reporter.nih.gov |
| Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,336,253 | May 20, 2022 | March 31, 2025 | POSTLER, THOMAS SIEGMUND | reporter.nih.gov |
| Imaging signatures of early tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,324,897 | November 9, 2023 | October 31, 2028 | XIE, YINGDA LINDA | reporter.nih.gov |
| A Rapid Phenotypic Drug Susceptibility Testing System for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,312,786 | August 23, 2024 | June 30, 2029 | KAMARIZA, MIREILLE | reporter.nih.gov |
| Mathematical modeling of Mycobacterium tuberculosis dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,312,263 | April 22, 2022 | March 31, 2027 | GANUSOV, VITALY V. | reporter.nih.gov |
| Improving outcomes in HIV-associated opportunistic infections using CNS pharmacokinetics and pharmacodynamics | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,308,986 | August 18, 2024 | May 31, 2029 | NICOL, MELANIE RAE | reporter.nih.gov |
| Research Training Program in Adolescent HIV in Haiti | NIH | Fogarty International Center | 2021 to 2024 | $1,305,920 | April 22, 2020 | December 31, 2025 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,298,050 | April 21, 2020 | March 31, 2026 | MEINTJES, GRAEME AYTON | reporter.nih.gov |
| Lung Ultrasound and Artificial Intelligence Technology for the Diagnosis of TB in LMICs | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,295,946 | February 15, 2024 | January 31, 2029 | GILMAN, ROBERT H | reporter.nih.gov |
| 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,295,893 | July 3, 2025 | June 30, 2027 | WARRICK, JAY WYATT | reporter.nih.gov |
| Novel nanoparticular diagnostics for cerebral toxoplasmosis and Chagas in HIV patients living in Latin America | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,293,572 | June 18, 2018 | May 31, 2024 | GILMAN, ROBERT H | reporter.nih.gov |
| Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,286,699 | April 6, 2020 | March 31, 2026 | SAMPSON, SAMANTHA LEIGH | reporter.nih.gov |
| Predicting tuberculosis outcomes using genotypic and biomarker signatures | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,282,364 | January 15, 2019 | June 14, 2022 | BEAMER, GILLIAN L | reporter.nih.gov |
| TB-TST (TB treatment support tools): Refinement and evaluation of an interactive mobile app and direct adherence monitoring on TB treatment outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,281,081 | June 19, 2019 | May 31, 2025 | RUBINSTEIN, FERNANDO ADRIÁN | reporter.nih.gov |
| METABOLIC REPROGRAMMING OF T CELL ENERGY METABOLISM IN TUBERCULOSIS AND HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,272,723 | April 1, 2018 | March 31, 2025 | STEYN, ADRIE JC | reporter.nih.gov |
| Defining drivers of TB transmission in the era of universal ART, and implications for finding the walking well | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,271,880 | August 8, 2019 | July 31, 2025 | GRANT, ALISON | reporter.nih.gov |
| Optimal tuberculosis screening and tuberculosis preventive therapy delivery strategies to improve maternal and birth outcomes among pregnant women with HIV in Uganda: a randomized trial | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,265,657 | September 20, 2025 | August 31, 2026 | YOON, CHRISTINA | reporter.nih.gov |
| TB detection in children using a novel stool-based GeneXpert assay | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,264,372 | December 5, 2017 | November 30, 2023 | ALLAND, DAVID | reporter.nih.gov |
| BCG overexpressing a small molecule STING agonist as a vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,261,288 | June 20, 2024 | July 31, 2028 | WALLACH, TODD | reporter.nih.gov |
| Evaluating the tuberculosis epidemic in South Africa using a novel ten-year cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,258,516 | April 13, 2020 | March 31, 2026 | SCOTT, LESLEY | reporter.nih.gov |
| Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,256,909 | September 5, 2024 | June 30, 2029 | DAVIS, JOHN LUCIAN | reporter.nih.gov |
| M. tuberculosis metabolites to activate human mucosal-associated invariant T cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,256,392 | June 1, 2023 | May 31, 2028 | HUANG, SHOUXIONG | reporter.nih.gov |
| Estimation of risk associated with zoonotic tuberculosis in South India | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,255,278 | February 20, 2024 | December 31, 2028 | KAPUR, VIVEK | reporter.nih.gov |
| Structural and Functional Characterization of RNA polymerase and its Regulators from Mycobacterium tuberculosis and Clostridioides difficile | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,247,663 | April 1, 2015 | May 31, 2024 | CAMPBELL, ELIZABETH A | reporter.nih.gov |
| Transcriptome and proteome remodeling by Mycobacterium tuberculosis MazF toxins | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,239,566 | December 1, 2019 | November 30, 2025 | WOYCHIK, NANCY ANN | reporter.nih.gov |
| Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options Trial | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,236,357 | August 1, 2018 | July 31, 2030 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,231,172 | July 15, 2012 | August 31, 2025 | KWARA, AWEWURA JACOB | reporter.nih.gov |
| Heart and Lung Outcomes Post-TB (HALO Post-TB) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,226,165 | September 25, 2024 | June 30, 2029 | HSUE, PRISCILLA Y. | reporter.nih.gov |
| Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,216,195 | September 19, 2025 | August 31, 2027 | WARRICK, JAY WYATT | reporter.nih.gov |
| Transcriptome and proteome remodeling by Mycobacterium tuberculosis MazF toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,215,943 | December 1, 2019 | November 30, 2022 | WOYCHIK, NANCY ANN | reporter.nih.gov |
| Building the Next Generation of Researchers in TB/HIV Diagnostics in Mali (B-NextGen) | NIH | Fogarty International Center | 2021 to 2024 | $1,203,194 | April 9, 2016 | March 31, 2026 | MURPHY, ROBERT LEO | reporter.nih.gov |
| Interplay between the Mtb electron transport chain and carbon metabolism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,197,306 | November 7, 2018 | October 31, 2024 | STEYN, ADRIE JC | reporter.nih.gov |
| THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,189,520 | February 16, 2023 | January 31, 2026 | NATHAVITHARANA, RUVANDHI | reporter.nih.gov |
| Regulation of Immune Responses to Mycobacterium tuberculosis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,188,492 | September 24, 2018 | August 31, 2024 | STALLINGS, CHRISTINA LEIGH | reporter.nih.gov |
| Studies of lipoamide dehydrogenase tight binding inhibition in tuberculous and non-tuberculous mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,188,030 | November 22, 2023 | October 31, 2028 | BRYK, RUSLANA | reporter.nih.gov |
| Emory-Georgia TB Research Training Program | NIH | Fogarty International Center | 2022 to 2025 | $1,187,449 | September 27, 2004 | February 28, 2027 | BLUMBERG, HENRY M | reporter.nih.gov |
| The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,184,815 | May 14, 2018 | April 30, 2025 | WANG, CHYUNG-RU | reporter.nih.gov |
| Infectiousness and social mixing in asymptomatic TB as a driver of population-level transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,173,748 | September 16, 2025 | August 31, 2030 | SHAH, NIPPIE SARITA | reporter.nih.gov |
| Targeting trained immunity and Th1/Th17 axis with combination adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,167,749 | July 26, 2021 | September 1, 2022 | KHADER, SHABAANA A. | reporter.nih.gov |
| Pathogen and host predictors of M. tuberculosis transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,166,933 | September 3, 2025 | August 31, 2030 | STERLING, TIMOTHY R | reporter.nih.gov |
| Testing of a Novel Inhaled Clofazimine (CFZ) Dry Powder Formulation in a Mouse Model of Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,164,080 | August 1, 2023 | June 30, 2025 | ENDSLEY, JANICE | reporter.nih.gov |
| Mathematical modeling of Mycobacterium tuberculosis dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,162,376 | April 22, 2022 | July 31, 2023 | GANUSOV, VITALY V. | reporter.nih.gov |
| Oral BCG: Optimizing mucosal vaccination against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,162,224 | April 24, 2025 | March 31, 2030 | LIN, PHILANA LING | reporter.nih.gov |
| Mitochondria as crucial regulators of innate immune outcomes during Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,157,211 | June 10, 2021 | May 31, 2027 | WATSON, ROBERT OWEN | reporter.nih.gov |
| 2/1 - Mongolian Center for Environmental & Occupational Health - Mongolia | NIH | Fogarty International Center | 2022 to 2025 | $1,156,208 | June 13, 2022 | February 28, 2027 | DAMBADARJAA, DAVAALKHAM - | reporter.nih.gov |
| Investigating the role of liquid-liquid phase separation in the interaction between Mycobacterium tuberculosis and macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,152,144 | August 10, 2021 | July 31, 2026 | BELL, SAMANTHA LYNN | reporter.nih.gov |
| Developing research leaders at the intersection of malnutrition and tuberculosis in Tanzania | NIH | Fogarty International Center | 2022 to 2025 | $1,145,152 | March 1, 2022 | February 28, 2027 | HEYSELL, SCOTT K | reporter.nih.gov |
| Disrupting Tuberculosis Transmission: Bacterial and Host Drivers of Mycobacterium Tuberculosis Aerosolization | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,141,359 | September 11, 2025 | August 31, 2030 | SHILOH, MICHAEL | reporter.nih.gov |
| PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,140,930 | July 1, 2018 | June 30, 2025 | GOLUB, JONATHAN E. | reporter.nih.gov |
| The role of nanocompartments in M. tuberculosis pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,139,634 | September 18, 2019 | August 31, 2025 | STANLEY, SARAH A | reporter.nih.gov |
| Post-Tuberculosis Lung Disease in Youth with and without HIV Globally | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,136,143 | August 22, 2025 | July 31, 2030 | ENANE, LESLIE ANNE | reporter.nih.gov |
| Dynamic allosteric communication within nonribosomal peptide synthetase cyclization domains | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,135,905 | June 1, 2013 | February 28, 2025 | FRUEH, DOMINIQUE PASCAL | reporter.nih.gov |
| Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,133,140 | February 1, 2019 | January 31, 2024 | LEWINSOHN, DAVID M. | reporter.nih.gov |
| High Dose Oral Rifampicin to Improve Survival from Adult Tuberculous Meningitis: a pharmacokinetic substudy (HARVEST-PK) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,122,044 | January 22, 2024 | November 30, 2028 | TE BRAKE, LINDSEY | reporter.nih.gov |
| Theory and Modeling of Functional Conformational Changes of RNA Polymerases | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,120,475 | June 1, 2023 | May 31, 2028 | HUANG, XUHUI | reporter.nih.gov |
| Wastewater surveillance to enhance the public health response to HIV and TB in Eswatini | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,120,000 | September 1, 2024 | July 31, 2029 | KAY, ALEXANDER WILLIAM | reporter.nih.gov |
| Conditional Expression of Mycobacterial Genes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,094,554 | February 15, 2006 | August 31, 2024 | EHRT, SABINE | reporter.nih.gov |
| Immunoregulation by indoleamine 2,3-dioxygenases in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,083,318 | May 1, 2018 | April 30, 2024 | CHAN, JOHN R. | reporter.nih.gov |
| New targets against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,076,804 | July 1, 2017 | June 30, 2023 | HUNG, DEBORAH T | reporter.nih.gov |
| Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,067,980 | March 1, 2023 | August 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| The Bacterial Genetic Basis of Bone Disease and Dissemination in Mycobacterial Infection: Roles of ESX-5 Secreted WXG Effectors | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,056,566 | August 15, 2017 | October 31, 2028 | TOBIN, DAVID M. | reporter.nih.gov |
| Khulani Siphile Siphuhle Training Program in South Africa (KiSS-TP) | NIH | Fogarty International Center | 2023 to 2025 | $1,042,352 | April 1, 2023 | March 31, 2029 | MEDINA-MARINO, ANDREW | reporter.nih.gov |
| Host-bacterial interactions determining the spectrum of Mtb transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,041,944 | September 11, 2025 | August 31, 2030 | SALGAME, PADMINI | reporter.nih.gov |
| Transmission Links and Clinical Spectrum of Exhaled Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,032,233 | September 10, 2025 | August 31, 2030 | XIE, YINGDA LINDA | reporter.nih.gov |
| The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $1,020,438 | January 16, 2020 | December 31, 2022 | CHAN, JOHN R. | reporter.nih.gov |
| Understanding HIV's impact on RR/MDR-TB development and transmission through genomics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,012,877 | June 1, 2025 | May 31, 2027 | BOUTON, TARA CATHERINE | reporter.nih.gov |
| Determinants of antigen specific CD4 T cell function in tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,006,392 | April 1, 2021 | September 30, 2026 | BOLD, TYLER DALLAS | reporter.nih.gov |
| Digital adherence technologies to facilitate completion of short-course tuberculosis preventive therapy among people living with HIV | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,005,750 | September 8, 2021 | August 31, 2026 | BERGER, CHRISTOPHER ALLEN | reporter.nih.gov |
| TOLLIP Deficiency, Immune Dysregulation, and Tuberculosis Susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,003,164 | March 1, 2018 | February 29, 2024 | SHAH, JAVEED ALI | reporter.nih.gov |
| Feasibility and acceptability of a peer-led strategy to improve community tuberculosis case finding among non-household contacts in Zambia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $999,000 | July 15, 2021 | June 30, 2026 | KERKHOFF, ANDREW | reporter.nih.gov |
| Bacterial Cell Wall Composition and the Influence of Antibiotics | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $997,488 | September 1, 2016 | May 31, 2025 | CEGELSKI, LYNETTE S | reporter.nih.gov |
| Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $996,798 | August 1, 2012 | July 31, 2024 | BUTLER, MICHELLE M. | reporter.nih.gov |
| The Transmission Biology of Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $974,300 | June 22, 2021 | May 31, 2027 | BROWN, CHRISTOPHER DAVID | reporter.nih.gov |
| Live nasal recombinant B. pertussis vaccine against tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $972,074 | May 4, 2022 | March 31, 2026 | GOLDSTEIN, PETER | reporter.nih.gov |
| Mechanisms of Viral Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $972,000 | December 1, 2009 | June 30, 2025 | BROOKS, DAVID G | reporter.nih.gov |
| Nitrosative stress and NO detoxifying reaction mechanisms in microbial nonheme diiron proteins | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $970,200 | April 1, 2023 | February 28, 2027 | MOENNE-LOCCOZ, PIERRE | reporter.nih.gov |
| Dissecting the genetic basis of protective immunity to tuberculosis in diverse hosts | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $966,000 | September 20, 2021 | August 31, 2026 | SMITH, CLARE MARGARET | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 13 | $588.3 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 5 | $431.4 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 11 | $196.9 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 63 | $179.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 60 | $125.6 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 20 | $117 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 36 | $62.4 million | 0 | $0 |
| Emory University | Atlanta, GA | 29 | $55.5 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 14 | $53.3 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 21 | $43.4 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 28 | $36.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 31 | $36 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 26 | $35.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 26 | $31.3 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 26 | $31.1 million | 0 | $0 |
| Wits Health Consortium (pty), LTD | Parktown | 5 | $30.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 11 | $30.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 6 | $29.7 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 12 | $26.5 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 6 | $25.4 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 16 | $25.3 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 13 | $24.7 million | 0 | $0 |
| University of Montana | Missoula, MT | 3 | $24.4 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 19 | $24 million | 0 | $0 |
| University of Cape Town | Rondebosch | 10 | $23.8 million | 0 | $0 |
| University of Chicago | Chicago, IL | 13 | $23 million | 0 | $0 |
| Stellenbosch University | Stellenbosch | 15 | $21.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 6 | $19.4 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 3 | $18.4 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 8 | $18.3 million | 0 | $0 |
| Universitat Bern | Bern | 1 | $16.8 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 17 | $16.8 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 13 | $16.6 million | 0 | $0 |
| Yale University | New Haven, CT | 17 | $16 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 8 | $15.8 million | 0 | $0 |
| Asociacion Civil Impacta Salud Y Educacn | Lima | 1 | $15.5 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 2 | $15.4 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 9 | $14.5 million | 0 | $0 |
| Centre/aids Programme/res/south Africa | Durban | 3 | $14.2 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 5 | $14.2 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 6 | $13.5 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 15 | $13.4 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 7 | $12.6 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 7 | $12.3 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 12 | $12.2 million | 0 | $0 |
| Duke University | Durham, NC | 15 | $11.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 11 | $11.2 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 5 | $11.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 10 | $11.1 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 14 | $11 million | 0 | $0 |
| University of Sydney | Sydney | 1 | $11 million | 0 | $0 |
| Gheskio Center | Port-Au-Prince | 2 | $11 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 4 | $10.9 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 1 | $10.7 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 6 | $10.4 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 15 | $10.3 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 1 | $9.9 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 8 | $9.8 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 3 | $8.7 million | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 1 | $8.3 million | 0 | $0 |
| Fundacao Oswaldo Cruz | Rio de Janeiro | 1 | $8.2 million | 0 | $0 |
| Cornell University | Ithaca, NY | 7 | $7.8 million | 0 | $0 |
| University of Florida | Gainesville, FL | 6 | $7.7 million | 0 | $0 |
| Stanford University | Stanford, CA | 7 | $7.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 6 | $7.6 million | 0 | $0 |
| Aurum Institute NPC | Parktown, Johannesburg | 2 | $6.8 million | 0 | $0 |
| University of Notre Dame | Notre Dame, IN | 7 | $6.5 million | 0 | $0 |
| Desmond Tutu Health Foundation | Cape Town | 4 | $6.4 million | 0 | $0 |
| Stichting Radboud Universitair Medisch Centrum I.o. | Nijmegen | 3 | $5.8 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 5 | $5.8 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 9 | $5.3 million | 0 | $0 |
| Pennsylvania State Univ University Park | University Park, PA | 3 | $5 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 10 | $5 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 2 | $4.9 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 4 | $4.8 million | 0 | $0 |
| PPD Development LP | Wilmington, NC | 1 | $4.7 million | 0 | $0 |
| Rockefeller University | New York, NY | 3 | $4.6 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 5 | $4.6 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 4 | $4.6 million | 0 | $0 |
| Institute for Systems Biology | Seattle, WA | 1 | $4.4 million | 0 | $0 |
| Wadsworth Center | Menands, NY | 5 | $4.4 million | 0 | $0 |
| Salus Discovery, LLC | Madison, WI | 3 | $4.3 million | 0 | $0 |
| Fimbrion Therapeutics, Inc. | Saint Louis, MO | 4 | $4.2 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 5 | $4.1 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 2 | $4 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 2 | $4 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 5 | $3.9 million | 0 | $0 |
| University of California-Santa Cruz | Santa Cruz, CA | 1 | $3.8 million | 0 | $0 |
| Starks Associates, Inc. | Buffalo, NY | 1 | $3.7 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 6 | $3.6 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 8 | $3.5 million | 0 | $0 |
| San Diego State University Foundation | San Diego, CA | 2 | $3.4 million | 0 | $0 |
| Oklahoma State University | Stillwater, OK | 2 | $3.4 million | 0 | $0 |
| Akonni Biosystems, Inc. | Frederick, MD | 2 | $3.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 4 | $3.3 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $3.1 million | 0 | $0 |
| Gryphon Scientific, LLC | Takoma Park, MD | 1 | $3 million | 0 | $0 |
| Triangle Biotechnology, Inc. | Chapel Hill, NC | 1 | $3 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 3 | $3 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 524 | $555,491,364 | 0 | $0 |
| 2024 | 545 | $560,034,747 | 0 | $0 |
| 2023 | 528 | $657,198,140 | 0 | $0 |
| 2022 | 531 | $774,034,432 | 0 | $0 |
| 2021 | 571 | $564,701,705 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 7 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 3 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) | PA-24-188 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) | PA-24-184 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | December 3, 2026 | Not listed | Notice number printed on 1 award here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | December 3, 2026 | Not listed | Notice number printed on 1 award here | |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | January 7, 2028 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 875 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 875 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 875 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 875 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 875 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 875 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.